Pennsylvanians: IRETA webinars are approved by the Pennsylvania Certification Board to provide credits for addictions practitioners and they satisfy Department of Drug and Alcohol Programs, Division of Drug and Alcohol Program Licensure training hour requirements.

New Yorkers: Although we are no longer providing NY OASAS CEUs, please note that New York does accept NAADAC.

Improving Clinical Quality in Methadone Treatment: Results of a 2-Year Pilot

January 23, 2019, 2:00pm ET, featuring Peter Luongo, PhD, and Dawn Lindsey, PhD

Register Here


There are more methadone programs in the U.S. today than there were five years ago. In fact, the methadone treatment industry grew more in the past four years than it has in the past two decades. That’s important in an opioid epidemic.

But IRETA has been working on another important aspect of methadone services: quality. In this webinar, we’ll describe our two-year clinical quality improvement project with a western Pennsylvania methadone program, which finished in October 2018. We’ll discuss lessons learned, client satisfaction, and ways to implement these ideas in your area.


Dr. Peter Luongo worked in the behavioral health field for over thirty years as a social worker and administrator before joining IRETA in 2011 as its Executive Director.

In Maryland, he was the Single State Authority under three governors as the Director of the Alcohol and Drug Administration. As the SSA, Dr. Luongo regulated the substance use disorder treatment industry across the state. He brings experience and expertise in clinical operations from an agency, local, and state system perspective.

Dr. Dawn Lindsey serves as IRETA’s Director of Research and Evaluation. She completed her PhD in Clinical Psychology at the University of Cincinnati, followed by an NIAAA-funded postdoctoral fellowship in alcohol epidemiology at the University of Pittsburgh.

She spent five years as an Assistant Professor in Psychiatry at Pitt researching substance use disorders in adolescents. In her post-academic life, IRETA offers Dawn the opportunity to apply her analytic skills to on the ground, real-world research problems.

Medication First: Reversing the Epidemic of Opioid-Related Mortality

March 20, 2019, 2:00pm ET, featuring Ned Presnall, LCSW

Register Here


Ned Presnall, LCSW, is executive director of Clayton Behavioral treatment programs in St. Louis, an adjunct professor and senior data analyst at Washington University in St. Louis, and a consultant for Missouri’s State Targeted Response to the Opioid Crisis. He divides his time between clinical work, education, and research.


In traditional treatment programs for addiction, the majority of patients are not offered ongoing medical treatment with opioid agonist medications. The minority who do receive medical care typically face intensive psychosocial service requirements that make access to medications both burdensome and costly. Others face arbitrary limitations on medical treatment that are associated with increased risk for morbidity and mortality.

Medication First programs get persons with opioid use disorder maintenance medical treatment as quickly as possible and provide voluntary supportive services as needed. A patient’s access to medical treatment is not dependent upon psychosocial treatment compliance or unrealistic expectations about the course of treatment and recovery. The Medication First approach is supported by decades of research. It prioritizes client choice in both service selection and service participation. There is a strong consensus in the scientific community that expanding the Medication First or “low-threshold” medical approach to opioid use disorder will be essential to reversing the epidemic of opioid-related deaths.